Photographer: Freya Ingrid Morales/Bloomberg

Roche Blood Cancer Medicine Fails to Show Major Improvement

Updated on
  • Success would have helped offset competition from biosimilars
  • Roche says it will continue to analyze Goya trial data

Swiss drugmaker Roche Holding AG said its blood cancer medicine Gazyva failed to show a significant improvement over its best-seller Rituxan, a setback in efforts to defend the aging blockbuster against copycats.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.